-
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies.
Gil MM, Quezada MS, Bregant B, Ferraro M, Nicolaides KH.
Ultrasound Obstet Gynecol 2013;42:34-40. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal serum retinol-binding protein-4 at 11-13weeks' gestation in normal and pathological pregnancies.
Nanda S, Nikoletakis G, Markova D, Poon LC, Nicolaides KH.
Metabolism 2013;62:814-9. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks' gestation and preeclampsia: a case-control study.
Khalil AA, Tsikas D, Akolekar R, Jordan J, Nicolaides KH.
J Hum Hypertens 2013;27:38-43. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54. -
Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?
Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C, Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H.
Placenta 2011;32:S4-16. -
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides KH.
Prenat Diagn 2011;31:66-74. -
First-trimester maternal serum PAPP-A, SP1 and M-CSF levels in normal and trisomic twin pregnancies.
Bersinger NA, Noble P, Nicolaides KH.
Prenat Diagn 2003;23:157-62. -
First trimester urine free beta hCG, beta core, and total oestriol in pregnancies affected by Down's syndrome: implications for first-trimester screening with nuchal translucency and serum free beta hCG.
Spencer K, Noble P, Snijders RJ, Nicolaides KH.
Prenat Diagn 1997;17:525-38. -
Maternal serum concentrations of pregnancy associated plasma protein A and pregnancy specific B-1 glycoprotein in multifetal pregnancies before and after fetal reduction.
Abbas A, Sebire NJ, Johnson M, Bersinger N, Nicolaides KH.
Hum Reprod 1996;11,900-2.